	US 11,981,715 B2
	Tissue targeted immunotolerance with a CD39 effector
Daniel Rios, Watertown, MA (US); Purvi Mande, Watertown, MA (US); Joanne L. Viney, Belmont, MA (US); Nathan Higginson-Scott, Boston, MA (US); Kevin Lewis Otipoby, Ashland, MA (US); Susmita Borthakur, Watertown, MA (US); Salvatore Alioto, Cambridge, MA (US); and Lindsay J. Edwards, Cambridge, MA (US)
Assigned to Pandion Operations, Inc., Rahway, NJ (US)
Filed by PANDION OPERATIONS, INC., Watertown, MA (US)
Filed on Feb. 18, 2021, as Appl. No. 17/178,926.
Claims priority of provisional application 62/979,881, filed on Feb. 21, 2020.
Prior Publication US 2021/0269496 A1, Sep. 2, 2021
Int. Cl. C07K 14/55 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01); C07K 14/705 (2006.01); C07K 16/28 (2006.01)

CPC C07K 14/55 (2013.01) [C07K 14/70596 (2013.01); C07K 16/28 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01)]

7 Claims

1. A polypeptide comprising a skin targeting moiety that binds to a target cell and an effector binding/modulating moiety, wherein the skin targeting moiety comprises an anti-desmoglein 1 antibody comprising a variable heavy domain having the amino acid sequence of SEQ ID NO: 65 and a variable light domain having the amino acid sequence of SEQ ID NO: 66, wherein the effector binding/modulating moiety is a CD39 Effector Domain, a PD-1 agonist, or an IL-2 mutein polypeptide (IL-2 mutein), wherein the IL-2 mutein comprises the sequence of SEQ ID NO: 60, wherein at least one of X₁, X₂, X₃, and X₄is I and the remainder are L or I.